Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for the extracellular peptide sequence PDTR of MUC1. It is utilized in breast cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Sontuzumab (AS1402), a humanized IgG1κ monoclonal antibody targeting MUC1, exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM for the extracellular peptide sequence PDTR of MUC1. It is utilized in breast cancer research [1]. |
In vitro | Sontuzumab (huHMFG-1; 0-25 μg/mL) induces antibody-dependent cellular cytotoxicity (ADCC) in the following cell lines: breast cancer ZR-75-1 cells, three myeloid tumor cell lines from breast cancer patients (KM22, 1590, HG15), and Chinese hamster ovary (CHO) cells transfected with the human MUC1 gene. Cell lines that do not express human MUC1 are insensitive to ADCC when Sontuzumab is present [1] [2]. |
Alias | huHMFG-1, AS1402 |
Cas No. | 372075-37-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.